Alliance Calls for European Pricing Transparency - - BioPharm International


Alliance Calls for European Pricing Transparency

BioPharm Bulletin

Believing that transparency in the pricing of medicines is “fundamental” to enabling patients and stakeholders to make proper decisions about equity and value for money in health systems, the European Public Health Alliance (EPHA) called for greater pricing transparency. EPHA also called for the formation of a public website that provides comparative information on medicines’ procurement prices. EPHA’s calls are a response to the European Commission’s consultation on the possible revision of Directive 89/105/EEC, which concerns the transparency of the pricing and reimbursement of medicines in various member states.

“The primary concern of EPHA is examining the effect of pricing transparency on the end user, that is to say the consumer of medicines. All patients are entitled to have timely access to high-quality, efficient, safe, essential medicines. No patient should be prohibited from accessing such medicines due to costs,” explained a statement from EPHA.

EPHA believes that the consultation should examine how transparency in medicines' pricing would place National Competent Authorities in a stronger position for negotiating prices when procuring medicines. In its statement, EPHA said: “Prices are often intransparent, as seen during the H1N1 pandemic in 2009, in which some Member States had had secrecy clauses written into their contracts for the procurement of the vaccine, meaning that others, lacking full information, were unable to negotiate effectively for a fair price.”

Another concern of EPHA is the timely availability of medicines. The alliance emphasizes that the time periods for pricing and reimbursement decisions laid down in the Directive should be adhered to.

“There is substantial evidence that in some [European Union] countries, pricing and reimbursement decisions are subject to unjustifiable delays, and in some countries there is an absence of effective sanctions. While we [recognize] there are obstacles to imposing sanctions through the Directive itself, the Directive can require Member States to ensure that effective remedies are available to affected parties (including patients) for breaches of the time limits,” said EPHA.

As a possible means of ensuring pricing transparency, EPHA cites a publicly accessible, regional database established by the World Health Organization that encourages the exchange of price information. “The Transparency Directive could establish such a website to provide comparative information on procurement prices for all medicines purchased by Member States. Such a database would also facilitate more rapid pricing decisions in those countries which operate external reference pricing schemes,” said EPHA.

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here